Why is Brawn Biotech falling/rising?

As of 14-Aug, Brawn Biotech Ltd's stock price is currently at 18.01, reflecting an increase of 0.85 or 4.95%. The stock has been gaining for the last two days, resulting in an overall return of 8.1% during this period. However, despite this recent uptick, the stock has underperformed in the longer term, with a year-to-date decline of 15.49% compared to a 3.15% increase in the Sensex. Additionally, the stock's delivery volume has significantly decreased, indicating falling investor participation, which could be a concern for future price stability. The company's long-term fundamentals are weak, with a negative return on equity and declining net sales, which may contribute to investor caution despite the recent price rise.
In the broader market context, Brawn Biotech's short-term performance has outpaced the Sensex, which has remained nearly flat at -0.03% over the past week. However, the stock's long-term trajectory is concerning, as it has declined by 33.42% over the past five years, while the Sensex has increased by 112.79% in the same period. This stark contrast highlights the challenges Brawn Biotech faces in maintaining investor confidence, especially given its weak financial metrics and negative EBITDA, which suggest that the stock may be trading at risky valuations despite its recent gains.